With new tech on board and assistance from Siemens Healthineers UBI looks almost zero risk.

Test strips aren't sexy but now they have so many patents, tech, commercialisation experience and industrial knowhow that surely a winner is close.

Unlike many other biotechs I wouldn't say this one is a constant dissapointer. I am hoping their ongoing discussions with other parties actually bring something.

Bought  a few more at 18.5. Not sure what Viburnum is doing, maybe a cheap T/O and offload in the US. Any ideas?